Nebula Research & Development LLC bought a new position in CorVel Co. (NASDAQ:CRVL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 12,742 shares of the business services provider's stock, valued at approximately $1,418,000.
A number of other institutional investors have also recently bought and sold shares of CRVL. Bessemer Group Inc. boosted its position in shares of CorVel by 6,350.0% during the 4th quarter. Bessemer Group Inc. now owns 258 shares of the business services provider's stock valued at $29,000 after acquiring an additional 254 shares in the last quarter. Fifth Third Bancorp boosted its holdings in CorVel by 45.9% during the fourth quarter. Fifth Third Bancorp now owns 321 shares of the business services provider's stock valued at $36,000 after purchasing an additional 101 shares in the last quarter. Jones Financial Companies Lllp bought a new stake in shares of CorVel in the 4th quarter valued at approximately $37,000. US Bancorp DE raised its holdings in shares of CorVel by 225.4% in the 4th quarter. US Bancorp DE now owns 384 shares of the business services provider's stock worth $43,000 after buying an additional 266 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of CorVel by 175.2% during the 4th quarter. GAMMA Investing LLC now owns 432 shares of the business services provider's stock worth $48,000 after buying an additional 275 shares during the period. Institutional investors and hedge funds own 51.36% of the company's stock.
Insider Buying and Selling at CorVel
In other CorVel news, Director Steven J. Hamerslag sold 10,000 shares of the firm's stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $123.48, for a total value of $1,234,800.00. Following the completion of the sale, the director now owns 314,000 shares in the company, valued at approximately $38,772,720. This trade represents a 3.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brandon O'brien sold 1,523 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $119.56, for a total transaction of $182,089.88. Following the transaction, the chief financial officer now owns 17,142 shares in the company, valued at $2,049,497.52. The trade was a 8.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,723 shares of company stock worth $5,757,140. 47.57% of the stock is currently owned by insiders.
CorVel Trading Down 0.7 %
Shares of CorVel stock traded down $0.75 during mid-day trading on Tuesday, reaching $109.00. 212,201 shares of the stock were exchanged, compared to its average volume of 118,476. The company has a market cap of $5.60 billion, a price-to-earnings ratio of 64.12 and a beta of 0.94. CorVel Co. has a fifty-two week low of $76.53 and a fifty-two week high of $128.61. The firm has a 50-day simple moving average of $110.39 and a 200 day simple moving average of $115.76.
CorVel (NASDAQ:CRVL - Get Free Report) last posted its earnings results on Tuesday, February 4th. The business services provider reported $0.46 earnings per share (EPS) for the quarter. CorVel had a net margin of 10.12% and a return on equity of 32.22%.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded CorVel from a "hold" rating to a "buy" rating in a research note on Friday, April 18th.
View Our Latest Stock Analysis on CRVL
About CorVel
(
Free Report)
CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
See Also
Before you consider CorVel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorVel wasn't on the list.
While CorVel currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
